Open AccessEffectiveness and safety of adjunctive traditional Chinese medicine therapy for primary liver cancer patients
Author(s) -
Tingting Li,
Xiaona Zhang,
Shanshan Xu,
Hongjie Cheng,
Hong Zhang
Publication year - 2020
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000021281
Subject(s) - medicine , randomized controlled trial , grading (engineering) , protocol (science) , evidence based medicine , traditional chinese medicine , meta analysis , alternative medicine , medline , medical physics , surgery , pathology , political science , law , civil engineering , engineering
Background: Traditional Chinese medicine (TCM) has gradually drawn the attention of clinicians as an alternative for Primary Liver Cancer (PLC), is based on the theory of syndrome differentiation. However, owing to the lack of evidence-based medical evidence, the authors designed this protocol to evaluate TCM's effectiveness and safety. Methods: Seven electronic databases will be searched from inception to Aug. 2020. Two of us will independently identify randomized controlled trials, extract the data and assess the risk of bias. The meta-analysis will be conducted with the Review Manager 5.3 software according the heterogeneity of eligible studies. Further, we will use the grading of recommendations assessment, development, and evaluation to evaluate the evidence quality. Results: This study will demonstrate an evidence-based review of TCM for PLC. Conclusion: The study will provide clear evidence to assess the effectiveness and side effects of TCM for PLC. Trial registration number: PROSPERO CRD 42020173748.